insights_auto
Why is HELP down 2.95%?
Dive Deeperchevron_right
HELP:NASDAQ
Helus Pharma Inc.
$10.19
arrow_downward
-2.95%(-0.31) 1D
$10.52
arrow_upward
+3.25% (+0.33)bedtimeAfter hours
Closed: Oct 23, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HELP...
Open
$10.50
High
$10.75
Low
$9.87
Avg. vol.
1.70M
Volume
1.89M
52-wk high
$15.15
52-wk low
$3.76
Beta
0.53
Shares outstanding
73.06M
No. of employees
100
Open
$10.50
High
$10.75
Low
$9.87
Avg. vol.
1.70M
Volume
1.89M
52-wk high
$15.15
52-wk low
$3.76
Beta
0.53
Shares outstanding
73.06M
No. of employees
100
News stories
From web sources and news partners
Bloomberg.com
·
8 hours ago
Zero-Day Option Traders Are Betting Against Big S&P 500 Swings
Seeking Alpha
·
2 hours ago
The S&P 500 Is At A Crossroads, That's A Buying Opportunity (SP500)
Profile
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, deupsilocin, deudimethyltryptamine, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, deupsilocin is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
About Helus Pharma Inc.
CEO-
Employees100
Founded2019
HeadquartersToronto, Ontario, Canada
SectorPharmaceutical industry
Websitehelus.com